Laursen Christian B, Naur Therese M H, Bodtger Uffe, Colella Sara, Naqibullah Matiullah, Minddal Valentina, Konge Lars, Davidsen Jesper R, Hansen Niels-Christian, Graumann Ole, Clementsen Paul F
*Department of Respiratory Medicine †Centre for Thoracic Oncology, Odense University Hospital ‡Institute for Clinical Research #Institute for Regional Health Research, University of Southern Denmark, Odense C §Department of Respiratory Medicine, Gentofte University Hospital, Hellerup ∥Copenhagen Academy for Medical Simulation and Simulation (CAMES), University of Copenhagen and the Capital Region of Denmark, Copenhagen ¶Department of Respiratory and Internal Medicine, Næstved Hospital, Næstved **Radiology Department, Aarhus University Hospital, Aarhus N ††Center of Clinical Ultrasound (CECLUS), Aarhus University, Aarhus C, Denmark.
J Bronchology Interv Pulmonol. 2016 Jul;23(3):220-8. doi: 10.1097/LBR.0000000000000297.
The aim of the study was to determine the diagnostic yield and prevalence of complications of ultrasound-guided transthoracic needle aspiration biopsies (US-TTNAB) performed by respiratory physicians after implementation of the procedure in an everyday clinical setting at 3 different centers.
Patients were included if they during the period from January 2012 to August 2014 had a registered US-TTNAB procedure code or if a US biopsy registration form had been filled out at either of the participating centers. Histology or cytology results were used as a reference test for diagnoses that could be made based on these results. Reference test for the remaining diagnoses was clinical follow-up. The diagnostic yield of US-TTNAB was defined as the proportion of patients in which the result of the US-TTNAB was consistent with the reference test.
A total of 215 patients in which a primary US-TTNAB had been performed were identified. The most common biopsy sites were lungs and pleurae with a total of 164 (76.3%) patients and 31 patients (14.4%), respectively. US-TTNAB diagnostic yield was 76.9% (95% CI, 70.3%-83.4%) for malignant diagnoses and 47.6% (95% CI, 31.9%-63.4%) for nonmalignant diagnoses. The most common complications of US-TTNAB were pneumothorax (2.5%; 95% CI, 0.03%-4.6%) and pain at the biopsy site (2%; 95% CI, 0.04%-3.9%). No fatalities related to US-TTNAB were observed.
US-TTNAB performed by respiratory physicians is a safe procedure with a low risk of complications and the diagnostic yield to establish a malignant diagnosis is acceptable.
本研究的目的是确定在3个不同中心的日常临床环境中实施超声引导下经胸针吸活检术(US-TTNAB)后,呼吸科医生进行该操作的诊断率及并发症发生率。
纳入2012年1月至2014年8月期间有登记的US-TTNAB操作代码,或在任何一个参与中心填写了US活检登记表的患者。组织学或细胞学结果用作基于这些结果可做出诊断的参考检测。其余诊断的参考检测为临床随访。US-TTNAB的诊断率定义为US-TTNAB结果与参考检测一致的患者比例。
共识别出215例接受初次US-TTNAB的患者。最常见的活检部位是肺和胸膜,分别有164例(76.3%)患者和31例(14.4%)患者。US-TTNAB对恶性诊断的诊断率为76.9%(95%CI,70.3%-83.4%),对非恶性诊断的诊断率为47.6%(95%CI, 31.9%-63.4%)。US-TTNAB最常见的并发症是气胸(2.5%;95%CI,0.03%-4.6%)和活检部位疼痛(2%;95%CI,0.04%-3.9%)。未观察到与US-TTNAB相关的死亡病例。
呼吸科医生进行的US-TTNAB是一种安全的操作,并发症风险低,建立恶性诊断的诊断率可接受。